DERM - Journey Medical Corp

https://journeymedicalcorp.com

Buy Momentum: Bearish

Recent News

Neutral

New Strong Sell Stocks for September 4th

Zacks Commentary • 1 week, 4 days ago • score: -0.13

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

Bullish

Journey Medical Corporation to Participate in September 2025 Investor Conferences

GlobeNewswire • 1 week, 5 days ago • score: 0.37

SCOTTSDALE, Ariz., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation ( "Journey Medical" or "the Company" ) ( Nasdaq: DERM ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ( "FDA" ) -approved prescription ...

Bullish

Journey Medical Corporation to Present at the Emerging Growth Conference - Fortress Biotech ( NASDAQ:FBIO ) , Journey Medical ( NASDAQ:DERM )

Benzinga • 4 weeks ago • score: 0.36

SCOTTSDALE, Ariz., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation DERM ( "Journey Medical," "the Company," "we" or "our" ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment ...

Bullish

Journey Medical Corporation to Present at the Emerging Growth Conference

GlobeNewswire • 4 weeks ago • score: 0.38

SCOTTSDALE, Ariz., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Journey Medical Corporation ( Nasdaq: DERM ) ( "Journey Medical," "the Company," "we" or "our" ) , a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the ...

Neutral

Journey Medical Corporation ( DERM ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.14

Journey Medical (DERM) delivered earnings and revenue surprises of -128.57% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks Commentary • 1 month ago • score: 0.22

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.

52W High

$8.90

52W Low

$3.54

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.81

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

28.01

EV/EBITDA (<8 favorable)

17.72

EV/Revenue (<3 favorable)

3.36

P/S (TTM) (<3 favorable)

3.27

P/B (<3 favorable)

9.58

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

33.05%

Institutions (25–75% balanced)

32.51%

Shares Outstanding

20,309,800

Float

12,808,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

56,397,000

Gross Profit (TTM)

37,517,000

EPS (TTM)

-0.37

Profit Margin (>10% good)

-0.16%

Operating Margin (TTM) (higher better)

-0.19%

ROE (TTM) (>15% strong)

-0.57%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.01

Momentum

Bearish momentum

Value

-0.0325

-0.0219

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025